DUBLIN, Sept. 14, 2018 /PRNewswire/ -- Allergan plc
(NYSE: AGN) today hosted its first ever Medical Aesthetics Analyst
Day where the Company outlined its industry-leading portfolio and
pipeline and key initiatives to drive future growth, as well as
presented an overview of the global medical aesthetics market.
"Since the first introduction of BOTOX® Cosmetic in
2002, Allergan has been a pioneer in creating the Medical
Aesthetics market. Today the Medical Aesthetics market is on the
cusp of a new era of extraordinary growth and Allergan is uniquely
positioned to build on its leadership position and double our
medical aesthetic business by 2025. Allergan consistently delivers
unparalleled innovation across our extensive Medical Aesthetics
portfolio and pipeline, along with superior provider experience and
service," said Brent Saunders,
Chairman and CEO of Allergan.
Business Has Potential to Double by 2025
Allergan's
Medical Aesthetics business – a comprehensive portfolio of facial
aesthetics, body contouring and plastic and regenerative medicine
products – is expected to grow at an 8-10 percent CAGR from 2017 to
2025. The business could generate net sales of approximately
$7 to $8
billion in 2025 from $3.8
billion in 2017.
Allergan to Leverage Dynamics in the Medical Aesthetics
Market
The Medical Aesthetic market, in the U.S. and
globally, is poised for significant growth, according to the
Allergan Business Analytics and Allergan 2016 Global Beauty Trends
Report. The expected growth is due to a number of compelling
factors such as:
- Attitudes and perceptions are evolving, with 65 percent of
respondents to the Allergan Global Beauty Survey saying that
aesthetic treatments have become more socially acceptable than 5
years ago. 71 percent are worried about wrinkles, while 41 percent
are considering medical aesthetic treatments.
- Approximately 65 million U.S. consumers and 153 million
internationally are currently considering facial injectable
treatments. Compared with the 4.2 million in the U.S. and the 10.5
million internationally who have had a treatment, only 6 to 7
percent of considerers have been moved to act.
- Millennials aesthetic users have more than tripled in the U.S.
during the last four years – at a rate that outpaces both Baby
Boomers and Gen X'ers – with over one million expected in
2018.
- Digital and social media is enabling the flow of information
and cultivating the "selfie-generation" as evidenced by the 50
million Google searches for Medical Aesthetics-related topics and
the 3.3 million #botox posts on Instagram.
- The number of providers worldwide has increased 40 percent from
2012 to 2017, resulting in a greater access to consultations and
treatments.
One-to-Two Product Launches Per Year Designed to Fuel
Allergan's Growth
Allergan's best-in-class Medical
Aesthetics R&D team expects to invest more than $1 billion on Medical Aesthetics innovation
through 2025 and expects to introduce one or two new products each
year between 2018 and 2025.
- Allergan will continue leadership with BOTOX®
Cosmetic by seeking three new indications; treatment of the
masseter muscle and platysma prominence, and skin quality. Allergan
will also develop a new BOTOX® Cosmetic delivery
configuration in pre-filled syringes.
- Allergan announced results of a higher dose BOTOX®
Cosmetic study for the treatment of moderate to severe glabellar
lines. The study met its primary endpoint confirming long-held
belief that higher doses of botulinum toxin produce greater
duration of treatment effect. Approximately one third of patients
in higher dose BOTOX® Cosmetic group were considered
responders at 24 weeks.
- Allergan agreed to acquire Bonti (subject to certain closing
conditions) to add rapid acting short duration botulinum neurotoxin
serotype E toxin programs to the R&D pipeline and to help
unlock demand from consumers who are first-time considerers of
medical aesthetics and who are looking for on demand
treatment.
- Allergan is developing a liquid formulation of a novel
neurotoxin, nivobotulinumtoxinA, and plans to initiate development
for glabellar lines and crow's feet lines.
- Allergan's JUVÉDERM® franchise will expand to
include treatments in development for the temple, tear trough, nose
and fine lines in the upper face, as well as lower facial shaping
for the jawline, chin, neck lines and décolletage.
- New topline data was presented on the use of TE-HA, the
hydrogel containing recombinant tropoelastin, gained as part of
Allergan's acquisition of Elastagen, for the treatment of adult
patients with acne scars. At 6 months, 21 of 27 (78%) patients
reported improvements in acne scar appearance. TE-HA also
demonstrated significant reduction in acne scar depth and volume
compared to the control group.
- CoolSculpting® is transforming into full face
and body contouring solutions with three breakthrough platforms
expected in the next three years including muscle conditioning,
skin tightening and cellulite.
- Plastic and Regenerative Medicine is continuing to
develop solutions for both the reconstruction and cosmetic settings
with further development of ARTIA™ in breast reconstruction surgery
and development of novel high-volume body fillers.
- Allergan R&D is currently reviewing multiple areas of unmet
need, including skin quality, skin tightening, cellulite and hair
loss.
"Allergan will continue driving innovation in Medical Aesthetics
into new frontiers, and the impact for patients will be profound,"
said David Nicholson, Allergan Chief
R&D Officer. "We have a best-in-class R&D operation that is
fully integrated globally and across pharma, device and
regenerative medicine. Allergan is excited about the potential for
delivering even more advanced innovation to patients across facial
aesthetics, body contouring and regenerative medicine in the years
to come."
Sales Force, Marketing and Support for Providers to
Expand
Allergan intends to increase the size of the U.S.
Facial Aesthetics sales force by 20 percent to increase service
levels and drive the expansion of the Company's reach by
approximately 5,000 practices and enable our representatives to
spend twice as much time with our top customers.
New ad campaigns for BOTOX® Cosmetic and
JUVÉDERM® will launch in the fourth quarter of 2018,
kicking-off Allergan's plan to double the Company's investment in
consumer marketing. The campaigns and the related promotional
efforts will heighten awareness with consumers, provide branded
information and remove some common barriers to treatment.
Increasing Training of Medical Aesthetics Providers to Meet
Demand for Medical Aesthetic Procedures and Improve
Outcomes
Through the Allergan Medical Institute, Allergan
trains more Medical Aesthetics practitioners in the appropriate use
and mastery of Medical Aesthetic products than all the aesthetic
companies combined. And, in 2019 Allergan expects to
substantially increase its training of Medical Aesthetics providers
to reach 80,000 providers globally.
Major Geographical Expansion Planned in Asia Pacific/Middle East Africa
- In China, Allergan
expects to double its Medical Aesthetics team by 2025 in order to
maximize the growth potential from the rapidly expanding market.
Allergan also expects to triple the number of Medical Aesthetics
accounts and injectors trained each year in China by 2025, with revenue on key products
rising as a result.
- Allergan plans to expand its opportunity beyond China by capitalizing on market growth in
Asia and the Middle East, with countries like
India, Indonesia and Vietnam being among the most rapidly
growing population centers and marketplaces globally.
"We truly have a unique opportunity in medical
aesthetics. Demand for products and services is on the rise
around the world due to the skill, dedication and commitment of
aesthetics providers. The best years in this field are ahead of
us," said Bill Meury, Allergan Chief Commercial Officer.
"Allergan is fully committed to serving its customers by
introducing innovative products and technologies, providing the
highest quality professional training, and educating
consumers. We are privileged to be a part of the medical
aesthetics community and look forward to partnering with
practitioners for years to come."
Strategic Partnerships and Key Initiatives are Key to Further
Growth
- Allergan and Alibaba's healthcare platform AliHealth announced
a strategic partnership in which the companies will launch a
medical aesthetics consumer education and consultation platform for
the Chinese market. The partnership is designed to further guide
Chinese consumers to choose qualified medical aesthetics hospitals,
doctors and products when pursuing treatment.
- Allergan announced the launch of Spotlyte™ – an unbranded
innovative digital hub of curated content that helps consumers
discover how medical aesthetic treatments may fit into their
routines. Through well-researched content, product reviews and
insider profiles, together with the latest beauty news and trends,
the site functions as a holistic and informative lens into these
worlds. Spotlyte™ will also provide access to a team
of trained specialists ready to offer real-time support
and chat directly with anyone considering medical aesthetic
treatments, as well as help connect readers to local licensed
providers.
- Allergan also announced its intent to form a collaboration with
HintMD, a subscription-based service administered through Medical
Aesthetics practices, to decrease barriers to patient acceptance of
Medical Aesthetics treatments.
Allergan
Contacts:
|
|
Investors:
|
|
Daphne
Karydas
|
(862)
261-8006
|
Karina
Calzadilla
|
(862)
261-7328
|
Media:
|
|
Amy
Rose
|
(862)
289-3072
|
Lisa
Brown
|
(862)
261-7320
|
About Allergan plc
Allergan plc (NYSE: AGN),
headquartered in Dublin, Ireland,
is a bold, global pharmaceutical leader. Allergan is focused
on developing, manufacturing and commercializing branded
pharmaceutical, device, biologic, surgical and regenerative
medicine products for patients around the world.
Allergan markets a portfolio of leading brands and best-in-class
products for the central nervous system, eye care, medical
aesthetics and dermatology, gastroenterology, women's health,
urology and anti-infective therapeutic categories.
Allergan is an industry leader in Open Science, a model of
research and development, which defines our approach to identifying
and developing game-changing ideas and innovation for better
patient care. With this approach, Allergan has built one of the
broadest development pipelines in the pharmaceutical industry.
Allergan's success is powered by our global colleagues'
commitment to being Bold for Life. Together, we build bridges,
power ideas, act fast and drive results for our customers and
patients around the world by always doing what is right.
With commercial operations in approximately 100 countries,
Allergan is committed to working with physicians, healthcare
providers and patients to deliver innovative and meaningful
treatments that help people around the world live longer, healthier
lives every day.
For more information, visit Allergan's website
at www.Allergan.com.
Forward-Looking Statement
Statements contained in this
press release that refer to future events or other non-historical
facts are forward-looking statements that reflect Allergan's
current perspective on existing trends and information as of the
date of this release. Actual results may differ materially from
Allergan's current expectations depending upon a number of factors
affecting Allergan's business. These factors include, among others,
our ability to successfully develop and commercialize new products;
the difficulty of predicting the timing or outcome of regulatory
approvals or actions, if any; the impact of competitive products
and pricing; market growth and market acceptance of and continued
demand for Allergan's products; the impact of uncertainty around
timing of generic entry related to key products on our financial
results; risks associated with acquisitions, mergers and joint
ventures; uncertainty associated with financial projections,
projected synergies, restructurings and increased costs;
difficulties or delays in manufacturing; and other risks and
uncertainties detailed in Allergan's periodic public filings with
the Securities and Exchange Commission, including but not limited
to Allergan's Annual Report on Form 10-K for the year ended
December 31, 2017 and Allergan's
Quarterly Report on Form 10-Q for the period ended June 30, 2018. Except as expressly required by
law, Allergan disclaims any intent or obligation to update these
forward-looking statements.
View original content to download
multimedia:http://www.prnewswire.com/news-releases/allergan-highlights-key-growth-drivers-for-medical-aesthetics-300713038.html
SOURCE Allergan plc